Response to vecuronium in a patient with facioscapulohumeral muscular dystrophy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 10655933.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Increased sensitivity to vecuronium has been noted in patients with Duchenne muscular dystrophy. We report the response to vecuronium in a patient with facioscapulohumeral muscular dystrophy (FSHD), an autosomal dominant disorder with an incidence of 10-20 cases per million. In this patient, sensitivity to an initial dose of vecuronium (0.02 + 0.08 mg kg-1) was normal, but recovery was faster and the effect of incremental doses of vecuronium (0.02 mg kg-1) was less than expected. Onset time and 25% recovery of T1/T0 after the intubating dose of vecuronium were 240 s and 22 min, respectively. Recovery index (spontaneous recovery of T1/T0 from 25% to 75%) was 9 min.
Medical subject headings
- Muscular Dystrophy, Facioscapulohumeral
- Neuromuscular Junction
- Neuromuscular Nondepolarizing Agents
- Vecuronium Bromide